AT₁-blockers in the treatment of hypertension: summary

Czech version

Authors: Jiří Widimský Jr
Authors‘ workplace: III. interní klinika 1. LF UK a VFN, Praha
Published in: Vnitř Lék 2016; 62(2): 107-113
Category: Reviews

Overview

Angiotensin receptor antagonists (AT₁-blockers) are considered as one of the major classes of antihypertensive drugs suitable for monotherapy as well as for combination treatment. AT₁-blockers have comparable antihypertensive efficacy with other major classes of antihypertensive drugs. AT₁-blockers are considered by current guidelines of Czech society of hypertension altogether with ACE-inhibitors and calcium channel blockers as universal antihypertensive drug class. AT₁-blockers has the lowest profile of side-effects among all antihypertensive drug classes and thus very high persistence to therapy. Mechanisms of antihypertensive effects of AT₁-blockers are discussed altogether with the results of large clinical trials and indications in the treatment of hypertension.

Key words:
AT₁-blockers – hypertension – treatment

Sources

1. Kaplan N. Victor RG. Kaplan’s Clinical Hypertension. 11th ed. Lippincott Williams and Wilkins: 2014. ISBN 978–1451190137.

2. Slíva J. Sartany v léčbě hypertenze. Acta medicinae 2015; 8: 2–7.

3. Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25(1): 41–46.

4. Weber MA. Angiotensin receptor blockers. In Izzo JL, Sica DA, Black R et al. Hypertension Primer: The Essentials of High Blood Pressure, Basic Science, Population Science, And Clinical Management. 4th ed. Lippincott Williams and Wilkins: 2007: 461–464. ISBN 978–0781782050.

5. Williams B, Lacourcière Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23(9): 610–619.

6. Conlin PR, Spence JD, Wiliams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13(4 Pt 1): 418–426.

7. 7.Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25(7): 1327–1336.

8. Bakris GL, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13(2): 81–88.

9. Neldam S, Edwards C, Jones R. TEAMSTA-10 Investigators.Switching patiens with uncotnrolled hypertension on amlodipin 10 mg to single –pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27(11): 1–9.

10. Rakugi H, Ogihara T, Miyata Y et al. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2012; 34(4): 838–848.

11. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–1559.

12. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze-verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785–801.

13. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357.

14. Fried LF, Emanuele N, Zhang JH et al (VA NEPHRON-D Investigators). Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892–1903.

15. Brenner BM, Cooper ME, de Zeeuw D et al (RENAAL Study Investigators). Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–869.

16. Parving HH, Lehnert H, Bröchner-Mortensen J et al. Irbesartan in Patients with Type-2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes. N Engl J Med 2001; 345(12): 870–878.

17. Lewis EJ, Hunsicker LG, Clarke WR et al (Collaborative Study Group). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860.

18. Dahlöf B, Devereux RB, Kjeldsen SE et al (LIFE Study Group). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995–1003.

19. Lithell H, Hansson L, Skoog I et al (SCOPE Study Group). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875–886.

20. Julius S, Kjeldsen SE, Weber M et al (VALUE Trial Group). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–2031.

21. Schrader J, Luders S, Kulschewski A et al (MOSES Study Group). Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218–2126.

22. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events, Profess study. N Engl J Med 2008; 359(12):1225–1237.

23. Petrella RJ , Shlyakhto E , Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens 2012; 14(2): 78–84.

24. Barnett AH, Bain SC, Bouter P et al.:Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351(19):1952–1961.

25. Špinar J, Vítovec J, Souček M et al. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitř Lék 2009; 55(5): 481–488.

26. Shih CJ1, Chen HT, Chao PW et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.. J Hypertens 2015. Dostupné z DOI: http://dx.doi.org/10.1097/HJH.0000000000000804.

27. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003; 16(12): 1066–1073.

28. Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens, 2008: 26(4) :819–824.

29. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol 2009; 8:18. Dostupné z DOI: http://dx.doi.org/10.1186/1475–2840–8-18.

30. Gosmanova EO, Lu JL, Streja E et al. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension 2014; 64(5): 951–957.